Biotechnology Today
more-
Amgen’s lupus bets continue to flounder, even those on the Horizon
Amgen’s lupus pursuits have encountered another pitfall, this time via potential acquisition of Horizon Therapeutics.
‘Unexpected’ cataracts in phase 3 trials end Kodiak’s hopes for eye drug, halving stock price
‘An unexpected outcome’: Bavarian Nordic crashes out of RSV race as vaccine fails phase 3 trial
University of Utah’s Bone Bolt system for complex fractures earns FDA clearance
Sleepless nights for 500 Idorsia staff as biotech halves cash burn to outlast weak insomnia drug sales
Markets
more-
Weekly Market Review – September 23, 2023
Stock Markets Investors’ reaction to rising U.S. Treasury yields and hawkish forecasts from the Federal…
Bio Space
more
The Infinity-MEI merger saga finally ends in shareholders sinking the deal
Infinity Pharmaceuticals’ merger saga has rumbled on almost as long…
Galen Robotics nets FDA de novo clearance for ENT surgery helper
Galen Robotics has claimed a de novo device clearance from…
Pfizer drops sickle cell disease collab with Syros inherited from GBT takeover
Pfizer is walking away from a sickle cell disease licensing…
Global News
more
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
Amgen’s lupus bets continue to flounder, even those on the Horizon
‘Unexpected’ cataracts in phase 3 trials end Kodiak’s hopes for eye drug, halving stock price
‘An unexpected outcome’: Bavarian Nordic crashes out of RSV race as vaccine fails phase 3 trial
University of Utah’s Bone Bolt system for complex fractures earns FDA clearance
The Infinity-MEI merger saga finally ends in shareholders sinking the deal
Galen Robotics nets FDA de novo clearance for ENT surgery helper
Pfizer drops sickle cell disease collab with Syros inherited from GBT takeover
Gilead’s $4.9B CD47 bet faces latest setback as company cans MDS ambitions for magrolimab
Sleepless nights for 500 Idorsia staff as biotech halves cash burn to outlast weak insomnia drug sales
Ex-B. Braun regulatory specialist pleads guilty to forging FDA clearance documents